| Literature DB >> 34885777 |
Shehla Akbar1, Saiqa Ishtiaq1, Muhammad Jahangir2, Sameh S Elhady3, Hanin A Bogari4, Abdelrahman M Alahdal4, Mohamed L Ashour5,6, Fadia S Youssef6.
Abstract
Phytochemical investigation of chloroform fraction (DBC) and ethyl acetate fraction (DBE) of D. bupleuroides (Acanthaceae) resulted in the isolation of β-sitosterol (1) from DBC and vanillic acid (2) from DBE, which were first to be isolated from D. bupleuroides. β-Sitosterol (1) exhibited substantial antioxidant activity (IC50 = 198.87 µg/mL), whereas vanillic acid (2) showed significant antioxidant power (IC50 = 92.68 µg/mL) employing 1,1-diphenyl-2-picrylhydrazyl (DPPH*) radical scavenging capacity assay. Both compounds showed pronounced antimicrobial activity using the agar disc diffusion method, particularly against fungi showing MIC values of 0.182 and 0.02 concerning Candida albicans, respectively, and 0.001 mg/mL regarding Penicillium notatum. They revealed considerable antibacterial activity with MIC values ranging between 0.467 and 0.809 mg/mL. Vanillic acid (2) exhibited substantial anticancer potential displaying 48.67% cell viability at a concentration of 100 μg/mL using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyl-2H-Tetrazolium Bromide) assay concerning HepG2 cell lines. These results were further consolidated by in silico studies on different enzymes, where vanillic acid displayed a high fitting score in the active pockets of DNA-gyrase, dihydrofolate reductase, aminoglycoside nucleotidyltransferase, and β-lactamase. It also inhibited human cyclin-dependent kinase 2 (CDK-2) and DNA topoisomerase II, as revealed by the in silico studies. ADME/TOPKAT (absorption, distribution, metabolism, excretion, and toxicity) prediction showed that vanillic acid exhibited reasonable pharmacodynamic, pharmacokinetic, and toxicity properties and, thus, could perfectly together with D. bupleuroides crude extract be incorporated in pharmaceutical preparations to counteract cancer and microbial invasion, as well as oxidative stress. Thus, it is concluded that D. bupleroides could be a potential source of therapeutically active compounds, which would be helpful for the discovery of clinically effective and safe drugs.Entities:
Keywords: Dicliptera bupleuroides; acanthaceae; anticancer activity; antimicrobial activity; antioxidant activity; molecular modeling; phytoconstituents
Mesh:
Substances:
Year: 2021 PMID: 34885777 PMCID: PMC8659019 DOI: 10.3390/molecules26237196
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Compounds isolated from D. bupleuroides chloroform and ethyl acetate fractions.
In vitro antioxidant activity evaluation for β-sitosterol (1) and vanillic acid (2) isolated from D. bupleuroides using 1,1-diphenyl-2-picrylhydrazyl (DPPH*) radical scavenging capacity assay.
| Sample | IC50 (µg/mL) |
|---|---|
| β-Sitosterol ( | 198.87 |
| Vanillic acid ( | 92.68 |
| Ascorbic acid | 125.86 |
% inhibition is measured in triplicates (n = 3) and presented as Mean ± SD. * Significantly different from the ascorbic acid group at p < 0.05.
MIC values of β-sitosterol (1) and vanillic acid (2) isolated from D. bupleuroides using disc diffusion assay and expressed in mg/mL.
| Microorganism | β-Sitosterol (1) | Vanillic Acid (2) | Ciprofloxacin | Fluconazole |
|---|---|---|---|---|
|
| 0.809 | 0.529 | 0.08 | NT |
|
| 0.700 | 0.486 | 0.05 | NT |
|
| 0.599 | 0.467 | 0.04 | NT |
|
| 0.672 | 0.492 | 0.06 | NT |
|
| 0.182 | 0.02 | NT | 0.12 |
|
| 0.001 | 0.001 | NT | 0.02 |
NT: not tested.
Figure 2Percentage cell viability of HepG2 cells in MTT assay exhibited by β-sitosterol (1) and vanillic acid (2) isolated from D. bupleuroides.
Binding energies (kcal/mole) of β-sitosterol (1) and vanillic acid (2) isolated from D. bupleuroides within the active sites of crucial microbial and cancer triggering enzymes.
| Examined Enzymes | β-Sitosterol | No of H–Bonds | Vanillic Acid | No of H–Bonds | Co-Crystalized Ligands | No of H–Bonds |
|---|---|---|---|---|---|---|
| Microbial Enzymes | ||||||
| DNA-gyrase | 56.45 | - | −24.26 | 1; Glu474 | −9.7 | 2; Asp435, Ser436 |
| Dihydrofolate reductase | 37.92 | 1; Arg32 | −26.63 | 2; Ile94, Asp27 | −28.90 | 3; Ile94, Ala7 |
| Aminoglycoside nucleotidyltransferase | 42.37 | 1; Glu101 | −25.21 | 2; Asp46, Asp86 | −20.03 | 8; Glu138, Asp86, Gly27, Leu47, Thr48 |
| β-Lactamase | 37.64 | - | −25.10 | 3; Ile117, Lys87, Ser84 | −61.76 | 7; Ile117, Lys87, Ser84, Ser142, Thr253, Lys250 |
| Anticancer Enzymes | ||||||
| Cyclin-dependent kinase 2 | 44.74 | - | −30.22 | 3; Asp145, Leu83 | −39.34 | 1; Leu83 |
| Matrix metalloproteinase 13 | 93.47 | 1; Phe241 | −29.34 | 3; Thr245, Ile243, Gly237 | −72.33 | 4; Thr245, Lys140, Thr247, Ala238 |
| DNA topoisomerase II | 53.85 | - | −22.07 | 2; Arg503, Glu237 | −0.2 | - |
The co-crystalized ligands are levofloxacin for DNA-gyrase; trimethoprim for dihydrofolate reductase; kanamycin for aminoglycoside nucleotidyltransferase; cefuroxime for β-lactamase; CK8, N-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-N′, N′-dimethyl benzene-1,4-diamine; for cyclin-dependent kinase 2; PB4, N, N′-bis (4-fluoro-3-methylbenzyl) pyrimidine-4,6-dicarboxamid for matrix metalloproteinase 13; doxorubicin for DNA topoisomerase II.
Figure 3Two-dimensional and 3D binding mode of vanillic acid (2) within the active site of DNA-gyrase (A), dihydrofolate reductase (B), and Aminoglycoside nucleotidyltransferase (C).
Figure 4Two-dimensional and 3D binding mode of vanillic acid (2) within the active site of cyclin-dependent kinase 2 (A), matrix metalloproteinase 13 (B), and DNA topoisomerase II (C).
Figure 5ADMET Plot for β-sitosterol (1) (circle) and vanillic acid (2) (star) isolated from D. bupleuroides displaying 95% and 99% confidence limit ellipses corresponding to the blood-brain barrier (BBB) and the human intestinal absorption models in ADMET_AlogP98.
ADME/TOPKAT (absorption, distribution, metabolism, excretion, and toxicity) evaluation of β-sitosterol (1) and vanillic acid (2) isolated from D. bupleuroides.
| Compounds | β-Sitosterol (1) | Vanillic Acid (2) |
|---|---|---|
|
| ||
| Absorption Level | 3 | 0 |
| Solubility Level | 0 | 4 |
| BBB Level | 4 | 3 |
| PPB Level | True | False |
| CPY2D6 | NI | NI |
| Hepatotoxic | Non-toxic | Non-toxic |
| PSA-2D | 8.08 | 1.20 |
| Alog p98 | 20.82 | 67.82 |
|
| ||
| Ames prediction | Non-mutagen | Non-mutagen |
| Rat chronic LOAEL (g/kg.bw) | 0.002 | 0.19 |
| Rat oral LD50 (g/kg.bw) | 1.57 | 2.39 |
| Rat female NPT | Non-carcinogen | Carcinogen |
| Rat Male NPT | Non-carcinogen | Non-carcinogen |
| Skin irritancy | Moderate | None |
| Ocular irritancy | None | Moderate |
0, 1, 2, and 3 indicates good, moderate, low, and very low absorption, respectively; 0, 1, 2, 3, 4, and 5 indicates extremely low, very low but possible, low, good, optimal, and too soluble, respectively; 0, 1, 2, 3, and 4 denote very high, high, medium, low, and undefined, penetration via BBB, respectively; PBB, plasma protein binding, FALSE means less than 90%, TRUE means more than 90%; NI: Non-inhibitor.